

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012482 A2

- (51) International Patent Classification⁷: C12N (74) Agent: LARSON, Marina, T.; Oppedahl & Larson LLP, P.O. Box 5068, Dillon, CO 80435 (US).
- (21) International Application Number: PCT/US2004/021297 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 30 June 2004 (30.06.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/483,806 30 June 2003 (30.06.2003) US
- (71) Applicant (for all designated States except US): SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH [US/US]; 1275 York Avenue, New York, NY 10021 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): CHIOSIS, Gabriela [RO/US]; c/o Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US). ROSEN, Neal [US/US]; c/o Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US). HUEZO, Henri [US/US]; c/o Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021 (US).
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY FOR IDENTIFICATION OF BIOACTIVE COMPOUNDS THAT INTERACT WITH HEAT SHOCK PROTEIN 90

(57) Abstract: A method for evaluation of molecules to identify those that can act as therapeutic inhibitors of Hsp90 makes use of a fluorescence polarization (FP) assay and a cell based assay, either individually or in combination. The FP assay uses a fluorescently-labeled Hsp90 binding agent and measure the degree of fluorescence polarization relative to the standard. A decrease in the degree of polarization indicates that fluorescently-labeled Hsp90 binding agent has been wholly or partially displaced by a candidate molecule, and identifies the molecule as having activity as an inhibitor of Hsp90. The cell based assay tests for decrease in an Hsp90-dependent activity of normal or tumor cells.



WO 2005/012482 A2

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012482 A3

(51) International Patent Classification⁷: **G01N 33/566**,
33/567, 21/21, 33/52, 33/53

(21) International Application Number:
PCT/US2004/021297

(22) International Filing Date: 30 June 2004 (30.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/483,806 30 June 2003 (30.06.2003) US

(71) Applicant (for all designated States except US):
**SLOAN-KETTERING INSTITUTE FOR CAN-
CER RESEARCH** [US/US]; 1275 York Avenue, New
York, NY 10021 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHIOSIS, Gabriela**
[RO/US]; c/o Office of Industrial Affairs, Memorial Sloan-
Kettering Cancer Center, 1275 York Avenue, New York,
NY 10021 (US). **ROSEN, Neal** [US/US]; c/o Office of In-
dustrial Affairs, Memorial Sloan-Kettering Cancer Center,
1275 York Avenue, New York, NY 10021 (US). **HUEZO,**
Henri [US/US]; c/o Office of Industrial Affairs, Memorial
Sloan-Kettering Cancer Center, 1275 York Avenue, New
York, NY 10021 (US).

(74) Agent: **LARSON, Marina, T.**; Oppedahl & Larson LLP,
P.O. Box 5068, Dillon, CO 80435 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with amended claims

(88) Date of publication of the international search report:
15 September 2005

Date of publication of the amended claims: 22 December 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ASSAY FOR IDENTIFICATION OF BIOACTIVE COMPOUNDS THAT INTERACT WITH HEAT SHOCK PRO-
TEIN 90

(57) Abstract: A method for evaluation of molecules to identify those that can act as therapeutic inhibitors of Hsp90 makes use of a
fluorescence polarization (FP) assay and a cell based assay, either individually or in combination. The FP assay uses a fluorescently-
labeled Hsp90 binding agent and measure the degree of fluorescence polarization relative to the standard. A decrease in the degree of
polarization indicates that fluorescently-labeled Hsp90 binding agent has been wholly or partially displaced by a candidate molecule,
and identifies the molecule as having activity as an inhibitor of Hsp90. The cell based assay tests for decrease in an Hsp90-dependent
activity of normal or tumor cells.

WO 2005/012482 A3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 February 2005 (10.02.2005)

PCT

(10) International Publication Number
WO 2005/012482 A3

(51) International Patent Classification⁷: **G01N 33/566**,
33/567, 21/21, 33/52, 33/53

(21) International Application Number:
PCT/US2004/021297

(22) International Filing Date: 30 June 2004 (30.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/483,806 30 June 2003 (30.06.2003) US

(71) Applicant (for all designated States except US):
**SLOAN-KETTERING INSTITUTE FOR CAN-
CER RESEARCH** [US/US]; 1275 York Avenue, New
York, NY 10021 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHIOSIS, Gabriela**
[RO/US]; c/o Office of Industrial Affairs, Memorial Sloan-
Kettering Cancer Center, 1275 York Avenue, New York,
NY 10021 (US). **ROSEN, Neal** [US/US]; c/o Office of In-
dustrial Affairs, Memorial Sloan-Kettering Cancer Center,
1275 York Avenue, New York, NY 10021 (US). **HUEZO,**
Henri [US/US]; c/o Office of Industrial Affairs, Memorial
Sloan-Kettering Cancer Center, 1275 York Avenue, New
York, NY 10021 (US).

(74) Agent: **LARSON, Marina, T.**; Oppedahl & Larson LLP,
P.O. Box 5068, Dillon, CO 80435 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
15 September 2005

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ASSAY FOR IDENTIFICATION OF BIOACTIVE COMPOUNDS THAT INTERACT WITH HEAT SHOCK PRO-
TEIN 90

(57) Abstract: A method for evaluation of molecules to identify those that can act as therapeutic inhibitors of Hsp90 makes use of a
fluorescence polarization (FP) assay and a cell based assay, either individually or in combination. The FP assay uses a fluorescently-
labeled Hsp90 binding agent and measure the degree of fluorescence polarization relative to the standard. A decrease in the degree of
polarization indicates that fluorescently-labeled Hsp90 binding agent has been wholly or partially displaced by a candidate molecule,
and identifies the molecule as having activity as an inhibitor of Hsp90. The cell based assay tests for decrease in an Hsp90-dependent
activity of normal or tumor cells.



WO 2005/012482 A3